Showing posts with label injections. Show all posts
Showing posts with label injections. Show all posts

Thursday, March 17, 2011

Animation of Orbital Insertion of Mercury spacecraft


NASA's MESSENGER mission, launched in 2004, is slated to slide into Mercury's orbit March 17 after a harrowing 4.7 billion mile journey that involved 15 loops around the sun and will bring relief and renewed excitement to the University of Colorado Boulder team that designed and a built an $8.7 million instrument onboard.

"In 2004, this milestone seemed like it was a long, long way away," said Senior Research Associate William McClintock, a mission co-investigator from CU-Boulder's Laboratory for Atmospheric and Space Physics. "But here we are at last, poised to help solve some of the many tantalizing mysteries about Mercury."

The smallest of the solar system's four rocky planets, Mercury is about two-thirds of the way nearer to the sun than Earth and has been visited by only one other spacecraft, NASA's Mariner 10, in 1974 and 1975. CU-Boulder scientists say learning what makes the hot, rocky planet tick will help them better understand the formation and evolution of planetary systems.

The refrigerator-sized spacecraft is carrying seven instruments -- a camera, a magnetometer, an altimeter and four spectrometers. Designed and built by CU-Boulder's LASP, the Mercury Atmospheric and Surface Composition Spectrometer, or MASCS, is a power-packed, 7-pound instrument that will make measurements of Mercury's surface and its tenuous atmosphere, called the exosphere.

MASCS breaks up light like a prism, and since each element and compound has a unique spectral signature, scientists can determine the distribution and abundance of various minerals and gases on the planet's surface and exosphere, said McClintock. "We now know Mercury's exosphere is constantly changing," he said.

During a 2009 MESSENGER flyby of Mercury, MASCS detected magnesium, an element created inside exploding stars, clumped in the exosphere. The team determined magnesium, sodium and potassium and several other kinds of atoms flying off Mercury's surface were being accelerated by solar radiation pressure to form a gigantic tail of material flowing away from the sun, said McClintock.

"All of the instruments on MESSENGER had to be extremely light, which stretched our imaginations and creativity," said LASP's Mark Lankton, program manager for MASCS. "We have learned a lot, and wound up getting a lot of bang for our buck."

LASP Director Daniel Baker, also a co-investigator on the MESSENGER mission, is studying Mercury's magnetic field and its interaction with the solar wind, including violent "sub-storms" that occur in the planet's vicinity. Since Mercury is the closest planet to the sun, MESSENGER is equipped with a large sunshade and heat-resistant ceramic fabric to protect it, said Baker.

"The three successful flybys of MESSENGER past Mercury have already rewritten the textbooks about the sun's nearest neighbor," Baker said. "We are pleased by all we have learned about the space environment of the planet. But we think there is so much more to learn -- we've probably just scratched the surface, so to speak."

Baker said the orbit insertion of Mercury will be celebrated by all of LASP, including a solar science team that saw its $28 million instrument crash into the sea March 4 due to problems with a NASA-contracted launch vehicle. "A very important aspect of LASP is that it is like a big family," Baker said. "Everyone shares the joys of success and the sorrow of failure, which has been a blessedly rare occurrence in our history."

"We have all of our appendages crossed for a successful orbit insertion," said Lankton. "MESSENGER is part of NASA's Discovery Program, and I'd be surprised if we don't continue to be surprised. Once we are in Mercury's orbit we are going to be getting a bounty of new data every day."

Sunday, September 6, 2009

Cancer: A Shot in the Arm or a shot in the Dark?

In 1999, two researchers at the National Cancer Institute (NCI) received a long-awaited green light to launch separate studies on cancer care.
Six months apart, Dr. Douglas Schwartzentruber and Dr. Larry Kwak (what an unfortunate name for a doctor! Change it now, to Dr Cure-all) began enrolling patients/subjects to test an entirely novel weapon in the war on cancer, one which they hoped would bypass the toxic effects of chemotherapy and give patients a new edge in halting the spread of tumours.

Both had the blessings of Dr. Richard Klausner, then NCI director. But even Klausner, a well-respected researcher, had to be persuaded at first. "I came to the NCI being quite skeptical about it," he says of the new strategy.

Unfortunately, he wasn't the only one. What Schwartzentruber and Kwak were hoping to do was prove they could vaccinate a patient against cancer — educate a body to, in essence, recognise and round up tumour cells the same way it polices viruses and bacteria.
It certainly made good biological sense: the immune system is the body's built-in defense mechanism, after all, so why not turn it against one of the most persistent diseases?

One of the problems, is that a tumour is not exactly a pathogen. What it is, at its core, is a collection of aggressively growing cells that can't stop dividing. It is not entirely foreign, in the same way that a virus is; it does not infect healthy cells, as bacteria and viruses do.
Turning the immune system against cancer cells would involve turning the body's defense mechanisms against a part of itself. Designing a vaccine to do this entails creating the biological version of a stealth weapon encased in a smart bomb equipped with a guided missile.

All this was proving to be a bit too challenging. Hundreds of researchers in hundreds of trials had attempted to solve this and nothing had worked. While the vaccine idea made logical sense, the immune system, it seemed, just wasn't designed to battle cancer this way.

Eventually, in June this year, after nearly a decade of carefully inoculating patients suffering from either advanced melanoma or a type of lymphoma, both Schwartzentruber and Kwak announced positive outcomes of their trials, at the American Society of Clinical Oncology meeting in Orlando, Fla.
Their results, along with those of a trial vaccine against prostate cancer and an early candidate against a type of brain cancer, suggest that we might finally be on the way to unleashing the immune system against the disease.